Zobrazeno 1 - 10
of 16
pro vyhledávání: '"John Simard"'
Autor:
Georgios Renieris, Eleni Karakike, Theologia Gkavogianni, Dionysia-Eirini Droggiti, Emmanouil Stylianakis, Theano Andriopoulou, Victoria-Marina Spanou, Dionyssios Kafousopoulos, Mihai G. Netea, Jesper Eugen-Olsen, John Simard, Evangelos J. Giamarellos-Bourboulis
Publikováno v:
Journal of Innate Immunity, Pp 1-14 (2022)
Acute respiratory distress syndrome (ARDS) in COVID-19 has been associated with catastrophic inflammation. We present measurements in humans and a new animal model implicating a role in danger-associated molecular patterns. Calprotectin (S100A8/A9) a
Externí odkaz:
https://doaj.org/article/9b7f3afeaabd4fd99ee0f1b4dcbd5292
Autor:
Razelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, Mark Saunders, Qian Wu, Michael Stecher, Prasant Mohanty, Charles A. Dinarello, John Simard
Publikováno v:
OncoImmunology, Vol 8, Iss 3 (2019)
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor. The effect
Externí odkaz:
https://doaj.org/article/6bbc56b8812c4fa0aab7838985140392
Autor:
Avanish K Varshney, Galina A Kuzmicheva, Jian Lin, Kevin M Sunley, Rodney A Bowling, Tzu-Yu Kwan, Heather R Mays, Anu Rambhadran, Yanfeng Zhang, Rebecca L Martin, Michael C Cavalier, John Simard, Sushma Shivaswamy
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190537 (2018)
Staphylococcus aureus can cause devastating and life-threatening infections. With the increase in multidrug resistant strains, novel therapies are needed. Limited success with active and passive immunization strategies have been attributed to S. aure
Externí odkaz:
https://doaj.org/article/cee8b261e24848b49ea2d2c8f81fb79b
Autor:
Jürg H. Beer, Giovanni G. Camici, Peter Libby, John Simard, Nicole R. Bonetti, Frank Ruschitzka, Yustina M. Puspitasari, Lena Schwarz, Alexander Akhmedov, Fabrizio Montecucco, Thomas F. Lüscher, Luca Liberale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95fada6a6bc6f2582186b552a89c1629
https://doi.org/10.5167/uzh-201097
https://doi.org/10.5167/uzh-201097
Autor:
Evangelos J. Giamarellos-Bourboulis, John Simard, Michael Stecher, Charles A. Dinarello, Themistoklis N. Spyridopoulos, Theodora Kanni, Aikaterini Pistiki, M. Argyropoulou
Publikováno v:
Journal of Investigative Dermatology. 138:795-801
Patients with moderate to severe hidradenitis suppurativa failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet need. Twenty patients not eligible for adalimumab were randomized to receive 12 weeks of blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8f1f1f5dd2a20046e25feeef60f5a35
https://doi.org/10.1016/j.jid.2017.10.030
https://doi.org/10.1016/j.jid.2017.10.030
Autor:
Judit Kocsis, Lucjan Wyrwicz, Wojciech Rogowski, Ron N. Apte, Aimery de Gramont, Thierry André, Prasant Mohanty, Krzysztof Lesniewski-Kmak, Tomasz Sarosiek, Radim Nemecek, Mark P Saunders, Tamas Hickish, Lubos Petruzelka, John Simard, Michael Stecher
Publikováno v:
The Lancet Oncology. 18:192-201
Summary Background MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2af64c58c0cc4b6c089ac6c9500059d
https://doi.org/10.1016/s1470-2045(17)30006-2
https://doi.org/10.1016/s1470-2045(17)30006-2
Autor:
Mark P Saunders, Tamas Hickish, Lucjan Wyrwicz, Razelle Kurzrock, Prasant Mohanty, Charles A. Dinarello, Qian Wu, Michael Stecher, John Simard
Publikováno v:
OncoImmunology, Vol 8, Iss 3 (2019)
Oncoimmunology
Oncoimmunology, vol 8, iss 3
Oncoimmunology
Oncoimmunology, vol 8, iss 3
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor. The effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478bda22181a4f516638daee8eaef889
https://doaj.org/article/6bbc56b8812c4fa0aab7838985140392
https://doaj.org/article/6bbc56b8812c4fa0aab7838985140392
Autor:
Filip Janku, John Simard, Siqing Fu, Apostolia Maria Tsimberidou, Sarina Anne Piha-Paul, Aung Naing, Gerald S. Falchook, Michael Stecher, David S. Hong, Razelle Kurzrock, Prasant Mohanty, Jennifer J. Wheler
Publikováno v:
Investigational New Drugs. 33:621-631
Background Advanced non-small cell lung cancer (NSCLC) patients were treated as part of a Phase I dose escalation and expansion study evaluating a true human monoclonal antibody targeting IL-1α (Xilonix), which is intended to modulate the malignant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7844f6af8535fd2d5baa38c5284d4e45
https://doi.org/10.1007/s10637-015-0226-6
https://doi.org/10.1007/s10637-015-0226-6
Publikováno v:
Clinical therapeutics. 39(11)
Purpose This review highlights the evidence supporting symptom control and quality-of-life (QOL) measures as predictors of survival in treatment-refractory metastatic colorectal cancer (mCRC) and describes a composite symptom control and QOL end poin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d31c55b3e7dcf23e244ba7b67cae808
https://pubmed.ncbi.nlm.nih.gov/29079389
https://pubmed.ncbi.nlm.nih.gov/29079389
Autor:
Eduardo Bruera, Siqing Fu, Apostolia Maria Tsimberidou, Michael Stecher, Filip Janku, David Hui, Razelle Kurzrock, John Simard, David S. Hong, Jennifer J. Wheler, Prasant Mohanty, Sarina Anne Piha-Paul, Gerald S. Falchook, Aung Naing
Publikováno v:
The Lancet Oncology. 15:656-666
Summary Background Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. We used a first-in-class, monoclonal antibody (MABp1) cloned from a human being to target int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8717c4c0c58a841de71aac21c8de120
https://doi.org/10.1016/s1470-2045(14)70155-x
https://doi.org/10.1016/s1470-2045(14)70155-x